S
Sensei Biotherapeutics, Inc. (SNSE)
NGM – Real Time Price. Currency in USD
13.85
+13.85 (0.00%)
At close: Jun 15, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
13.85
+13.85 (0.00%)
At close: Jun 15, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $152.3M significantly exceed its total debt $1.0M, ensuring strong financial flexibility
Total current assets $204.2M exceed Total current liabilities $14.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-28,970.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$10.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.39 | 6.05 | 10 | |
| Quick ratio | 14.39 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | -28970.00 | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -2M | -571K | -551K | -139K | -135K |
| Operating Income | -49M | -37M | -32M | -22M | -44M |
| Net Income | -49M | -34M | -30M | -21M | -184M |
| EBITDA | -47M | -36M | -31M | -22M | -44M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 9.34 | 3.5 |
| Next quarter | N/A | -6.54 | 1.0 |
| Current year | N/A | -691.77 | 1.0 |
| Next year | N/A | 95.07 | 5.5 |
| Weighted average score | 2.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -3508.98 | -3368.33 | -177.91 | 3.3 |
| Y/Y | 999 | -2380.12 | -2334.25 | -51.37 | 3.3 |
| 3y average | 999 | 23.82 | 18.25 | 19.54 | 9.5 |
| 5y average | 999 | -8.71 | 25.07 | -6.78 | 5.5 |
| Weighted average score | 5.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |